FDA Clears IND for GT-02287, Advancing Parkinson's Drug to Phase 2 in US
GANX sits 72% above its 52-week low of $1.41 on elevated volume (8.6× avg).
Summary
Gain Therapeutics received FDA clearance for its GT-02287 Investigational New Drug application, enabling the initiation of Phase 2 clinical trials in the U.S. for Parkinson's disease.
Key Events · Product Development and Regulatory · GANX
-
FDA IND Clearance
The U.S. Food and Drug Administration (FDA) has authorized Gain Therapeutics' Investigational New Drug (IND) application for GT-02287.
-
Phase 2 Clinical Trial Expansion
This clearance allows the initiation of Phase 2 clinical development of GT-02287 for Parkinson's disease in the U.S., expanding beyond existing sites in Australia and new European centers.
-
Anticipated Q3 2026 Start
The planned Phase 2a study of oral GT-02287 is expected to begin in the third quarter of 2026.
Analysis · GANX · Life Sciences
This FDA clearance is a critical step for Gain Therapeutics, allowing them to expand their Phase 2 clinical trial for GT-02287 into the U.S. for Parkinson's disease. Given the company's recent "going concern" warning, advancing their lead candidate is essential for demonstrating progress and securing future funding. This development significantly de-risks the drug's path forward and provides a clear timeline for the next stage of clinical development.
At the time of this filing, GANX was trading at $2.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $1.41 to $4.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.